Bristol Myers wins a megablockbuster bet with TYK2 FDA approval — and there’s a big bonus for the label – Endpoints News

PARIS — Last fall Deciphera suffered through a disastrous setback $DCPH with its lead drug, Qinlock, which had been approved as a fourth-line therapy for gastrointestinal stromal tumors (GIST) but then failed in an attempt to move upstream in the treatment scenario — essentially relegating it to minor sales revenue instead of the blockbuster potential some analysts had painted.

That knockdown, which sent its stock into a tailspin the biotech has not recovered from, forced the Deciphera team to undergo a thorough reassessment of the pipeline, and a move to cull its work and focus on the clinical program for vimseltinib, a CSF1R inhibitor being studied as a therapy for tenoysynovial giant cell tumor — or TGCT.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,100+ biopharma pros reading Endpoints daily — and it’s free.

Leave a Comment

Your email address will not be published.

%d bloggers like this: